Table V.
Annual Average Cost by Class of Drug Prescribed at Enrollment and Persistence Pattern
| Average Cost for Continuers (ɛ [95% CI]) | Average Cost for Switchers (ɛ [95% CI]) | Average Cost for Discontinuers (ɛ [95% CI]) | Average Cost for Study Cohort (ɛ [95% CI]) | |
|---|---|---|---|---|
| Diuretics | 65.09 | 153.10 | 8.17 | 33.45 |
| (58.67–71.52) | (137.59–168.62) | (7.60–8.75) | (30.97–35.93) | |
| β Blockers | 109.29 | 158.73 | 22.52 | 63.40 |
| (102.46–116.12) | (139.61–177.84) | (21.24–23.79) | (59.94–66.86) | |
| CCBs | 234.63 | 199.62 | 38.24 | 104.43 |
| (224.78–244.47) | (183.45–215.78) | (36.78–39.70) | (100.07–108.79) | |
| ACE inhibitors | 196.28 | 237.53 | 34.76 | 108.25 |
| (189.69–202.86) | (222.28–252.79) | (33.53–35.99) | (104.43–112.09) | |
| AIIAs | 326.16 | 268.07 | 67.10 | 201.53 |
| (313.05–339.27) | (241.55–294.59) | (62.89–71.31) | (191.24–211.81) | |
| Total | 171.73 | 205.10 | 28.29 | 88.09 |
| (167.43–176.04) | (196.85–213.34) | (27.62–28.97) | (86.10–90.08) | |
| CI=confidence interval; CCBs=calcium channel blockers; ACE=angiotensin‐converting enzyme; AIIAs=angiotensin II receptor antagonists | ||||